Targeting micro-environmental pathways by PROTACs as a therapeutic strategy

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• The tumor microenvironment (TME) comprises diverse cellular and non-cellular elements that foster tumor growth, metastasis, and immune evasion.
• The TME also contributes significantly to therapeutic resistance, limiting the efficacy of conventional treatments.
• Small molecule inhibitors (SMIs) and antibodies targeting TME components are established cancer treatment strategies.

Purpose of the Study:

• To review recent advancements in PROteolysis-TArgeting Chimera (PROTAC) development targeting the tumor microenvironment (TME).
• To explore the advantages of PROTACs over traditional therapies, particularly in overcoming drug resistance.
• To propose future directions for PROTAC technology in cancer treatment.

Main Methods:

• Literature review of recent studies on PROTACs targeting TME pathways.
• Analysis of PROTAC mechanisms, advantages, and limitations compared to SMIs and antibodies.
• Synthesis of current progress and future perspectives in PROTAC-based cancer therapy.

Main Results:

• PROTACs demonstrate significant potential in targeting specific components within the TME.
• PROTACs offer a promising strategy to overcome resistance mechanisms associated with conventional cancer therapies.
• Numerous PROTACs targeting TME pathways are under active development for cancer treatment.

Conclusions:

• PROTAC technology represents a promising frontier in cancer therapy, particularly for targeting the complex TME.
• Further development of PROTACs holds the potential to overcome existing therapeutic challenges and improve patient outcomes.
• Future research should focus on optimizing PROTAC design and delivery for enhanced efficacy against TME-driven cancers.